Literature DB >> 21964585

A longitudinal model for magnetic resonance imaging lesion count data in multiple sclerosis patients.

Rachel MacKay Altman1, A John Petkau, Dean Vrecko, Alex Smith.   

Abstract

Magnetic resonance imaging (MRI) data are routinely collected at multiple time points during phase 2 clinical trials in multiple sclerosis. However, these data are typically summarized into a single response for each patient before analysis. Models based on these summary statistics do not allow the exploration of the trade-off between numbers of patients and numbers of scans per patient or the development of optimal schedules for MRI scanning. To address these limitations, in this paper, we develop a longitudinal model to describe one MRI outcome: the number of lesions observed on an individual MRI scan. We motivate our choice of a mixed hidden Markov model based both on novel graphical diagnostic methods applied to five real data sets and on conceptual considerations. Using this model, we compare the performance of a number of different tests of treatment effect. These include standard parametric and nonparametric tests, as well as tests based on the new model. We conduct an extensive simulation study using data generated from the longitudinal model to investigate the parameters that affect test performance and to assess size and power. We determine that the parameters of the hidden Markov chain do not substantially affect the performance of the tests. Furthermore, we describe conditions under which likelihood ratio tests based on the longitudinal model appreciably outperform the standard tests based on summary statistics. These results establish that the new model is a valuable practical tool for designing and analyzing multiple sclerosis clinical trials.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21964585     DOI: 10.1002/sim.4394

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Authors:  Kerstin Bendfeldt; Bernd Taschler; Laura Gaetano; Philip Madoerin; Pascal Kuster; Nicole Mueller-Lenke; Michael Amann; Hugo Vrenken; Viktor Wottschel; Frederik Barkhof; Stefan Borgwardt; Stefan Klöppel; Eva-Maria Wicklein; Ludwig Kappos; Gilles Edan; Mark S Freedman; Xavier Montalbán; Hans-Peter Hartung; Christoph Pohl; Rupert Sandbrink; Till Sprenger; Ernst-Wilhelm Radue; Jens Wuerfel; Thomas E Nichols
Journal:  Brain Imaging Behav       Date:  2019-10       Impact factor: 3.978

2.  Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

Authors:  Kumar Kandadi Muralidharan; Deb Steiner; Diogo Amarante; Pei-Ran Ho; Dan Mikol; Jacob Elkins; Meena Subramanyam; Ivan Nestorov
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-01       Impact factor: 2.745

3.  Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients.

Authors:  Yaming Hang; Xiao Hu; Jie Zhang; Shifang Liu; Aaron Deykin; Ivan Nestorov
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-06-14       Impact factor: 2.745

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.